{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:51:09Z","timestamp":1782190269030,"version":"3.54.5"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The efficacy of Oxford classification in guiding immunotherapy management strategies remains a subject of debate. Our study aimed to explore different combinations of Oxford Classification activity scores in guiding immunotherapy for IgA nephropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We introduced a sum scores to analyze composite pathological score association with immunotherapy for proteinuria remission, aiming to further elucidate the clinical utility of renal histology in immunotherapy decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 3,196 patients were diagnosed with IgA nephropathy, as confirmed by renal biopsy, between May 2018 and November 2023. However, only 2,389 patients were enrolled after the exclusion criteria were applied. The cohort included 1,211 patients receiving immunosuppressive therapy and 1,178 patients managed with supportive care. Patients with complete outcomes were selected, and the characteristics between groups were balanced using propensity score matching. We subsequently employed both Kaplan-Meier and Cox regression analyses to investigate the impact of immunotherapy on proteinuria remission. We defined SumMEC (the sum of the M, E, and C scores) as a potential immunotherapy responsiveness score. Furthermore, we conducted a subgroup analysis to explore the association between different SumMEC subgroups and the effect of immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A multivariate Cox regression analysis revealed that immunotherapy was associated with a 22% increase in proteinuria remission at 12 months in patients with IgAN (HR 1.22; 95% CI 1.07-1.40; p=0.004). Subgroup analyses demonstrated this benefit only in patients with high SumMEC scores. The effects of immunotherapy and the SumMEC score on 6-month proteinuria remission are comparable to those observed at 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The use of immunosuppressive agents may improve proteinuria remission in patients with IgA nephropathy. Patients with high SumMEC scores responded positively to immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1873181","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:35:35Z","timestamp":1782189335000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Guiding immunotherapy based on the oxford classification activity score in IgA nephropathy"],"prefix":"10.3389","volume":"17","author":[{"given":"Jingjing","family":"Nong","sequence":"first","affiliation":[{"name":"Division of Nephrology, The First Affiliated Hospital of Guilin Medical University","place":["Guilin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Tang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, The First Affiliated Hospital of Guilin Medical University","place":["Guilin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhen","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, The First Affiliated Hospital of Guilin Medical University","place":["Guilin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Wei","sequence":"additional","affiliation":[{"name":"Division of Nephrology, The First Affiliated Hospital of Guilin Medical University","place":["Guilin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licong","family":"Su","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Guangdong Provincial Clinical Research Center for Kidney Disease","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Nie","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Guangdong Provincial Clinical Research Center for Kidney Disease","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ou","sequence":"additional","affiliation":[{"name":"Division of Nephrology, The First Affiliated Hospital of Guilin Medical University","place":["Guilin, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"B1","article-title":"Les ddp\u00f4ts intercapillaires d'IgA-IgG [intercapillary deposits of IgA-IgG","volume":"74","author":"Berger","year":"1968","journal-title":"J Urol Nephrol Paris"},{"key":"B2","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2024.2411846","article-title":"Predictive role of Oxford classification for prognosis in children with IgA nephropathy: a systematic review and meta-analysis","volume":"46","author":"Liu","year":"2024","journal-title":"Ren Fail"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.322","article-title":"The MEST score provides earlier risk prediction in IgA nephropathy","volume":"89","author":"Barbour","year":"2016","journal-title":"Kidney Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac025","article-title":"Indication for corticosteroids in IgA nephropathy: validation in the European VALIGA cohort of a treatment score based on the Oxford classification","volume":"37","author":"Cambier","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq387","article-title":"Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination\/prednisolone therapy","volume":"26","author":"Shima","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-015-0227-8","article-title":"Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression","volume":"29","author":"Chakera","year":"2016","journal-title":"J Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-014-0165-x","article-title":"Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation","volume":"28","author":"Shen","year":"2015","journal-title":"J Nephrol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae364","article-title":"Factors influencing early response of IgA nephropathy following targeted-release budesonide (TRB) treatment: preliminary results from a multicenter study","volume":"18","author":"Keskinis","year":"2024","journal-title":"Clin Kidney J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ekir.2021.10.007","article-title":"A novel scoring system based on Oxford classification indicating steroid therapy use for IgA nephropathy","volume":"7","author":"Itami","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102657","article-title":"Identification and external validation of IgA nephropathy patients benefiting from immunosuppression therapy","volume":"52","author":"Chen","year":"2020","journal-title":"EBioMedicine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial","volume":"69","author":"Hou","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000796","article-title":"Predictive value of the Oxford classification for the effect of glucocorticoid therapy in IgA nephropathy","volume":"37","author":"Shi","year":"2026","journal-title":"J Am Soc Nephrol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-014-3041-y","article-title":"Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children","volume":"30","author":"Kang","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000497808","article-title":"Clinical significance of crescent formation in IgA nephropathy - a multicenter validation study","volume":"44","author":"Park","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.04.003","article-title":"Executive summary of the KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Floege","year":"2025","journal-title":"Kidney Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2025.03.008","article-title":"Corticosteroid effects in IgA nephropathy by baseline proteinuria and estimated GFR","volume":"10","author":"Kim","year":"2025","journal-title":"Kidney Int Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S383138","article-title":"Insights on Nefecon\u00ae, a targeted-release formulation of budesonide and its selective immunomodulatory effects in patients with IgA nephropathy","volume":"18","author":"Barratt","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1159\/000547868","article-title":"The association of proteinuria target achievement timing and stability with adverse kidney outcomes among patients with IgA nephropathy: a cohort study","volume":"6","author":"Li","year":"","journal-title":"Am J Nephrol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ndt\/gfae151","article-title":"The use of albuminuria or proteinuria for risk prediction in IgAN","volume":"40","author":"Cheung","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-021-00882-9","article-title":"Complement activation in IgA nephropathy","volume":"43","author":"Medjeral-Thomas","year":"2021","journal-title":"Semin Immunopathol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040495","article-title":"Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy","volume":"7","author":"Kim","year":"2012","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.11.005","article-title":"Systematic review of the link between Oxford MEST-C classification and complement activation in IgA nephropathy","volume":"9","author":"\u0218tefan","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07420716","article-title":"IgA nephropathy","volume":"12","author":"Rodrigues","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-007-0089-9","article-title":"Immunopathogenesis of igan","volume":"29","author":"Barratt","year":"2007","journal-title":"Semin Immunopathol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.02.023","article-title":"Circulating complement factor H-related protein 5 levels contribute to development and progression of IgA nephropathy","volume":"94","author":"Zhu","year":"2018","journal-title":"Kidney Int"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-020-02800-0","article-title":"Complement activation is associated with crescent formation in IgA nephropathy","volume":"477","author":"Itami","year":"2020","journal-title":"Virchows Arch"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw326","article-title":"Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment","volume":"32","author":"Beckwith","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.03.011","article-title":"Evidence from the large VALIGA cohort validates the subclassification of focal segmental glomerulosclerosis in IgA nephropathy","volume":"105","author":"Bellur","year":"2024","journal-title":"Kidney Int"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy302","article-title":"Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford classification for IgA nephropathy (VALIGA) update","volume":"35","author":"Coppo","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm560","article-title":"Prediction of early progression in recently diagnosed IgA nephropathy","volume":"23","author":"Lemley","year":"2008","journal-title":"Nephrol Dial Transplant"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1873181\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:35:40Z","timestamp":1782189340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1873181\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":38,"alternative-id":["10.3389\/fendo.2026.1873181"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1873181","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"1873181"}}